PVC-Induced Cardiomyopathy: Ablation or a Trial of Antiarrhythmic Drugs First
A single patient whose heart weakened for a reason that's unusually reversible, if it's caught and treated correctly. The disagreement is about whether a procedure or a prescription is the more direct way to reverse it.
L.B., a 45-year-old woman, directs the choir at her local high school, a job that has her on her feet conducting rehearsal most weekday afternoons and most weekend performances besides. She noticed an unfamiliar fluttering sensation in her chest a few months ago, persistent enough that she finally mentioned it at a routine physical. A 24-hour Holter monitor found a premature ventricular contraction burden of 24% — nearly a quarter of her heartbeats — and an echocardiogram found a newly reduced ejection fraction of 40%, down from a normal study two years earlier, with no further structural abnormality and no prior history of heart disease.
PVC-induced cardiomyopathy is a real, distinct diagnosis: a sustained high burden of ectopic beats can itself weaken the heart over time, through a mechanism separate from any underlying structural disease, and the cardiomyopathy often reverses once the ectopy burden is brought down. That reversal potential is exactly what's shaping the team's disagreement — catheter ablation can be genuinely curative if her PVC focus originates somewhere mappable and accessible, while antiarrhythmic drug therapy can also suppress the ectopy burden enough to let the heart recover, without a procedure at all. Preliminary mapping already suggests her focus sits in an easily accessible location, which matters directly for how confidently ablation can be offered as more than a theoretical option. She has already had to hand rehearsal duties off to her assistant director twice this month when the fatigue from her reduced ejection fraction caught up with her mid-session, which is part of why she wants a clear answer sooner rather than later.
A procedure or a prescription
I'd go straight to catheter ablation. Her mapping already points to an accessible outflow-tract focus, which is exactly the profile where ablation has its best success rates and can be genuinely curative — not just management, an actual end to the arrhythmia burden that's weakening her heart. That avoids committing her to an antiarrhythmic drug she may need to take indefinitely, with its own real side-effect burden, for a problem a single procedure could resolve outright.
I'd try a medication first. Ablation carries real procedural risk, even at accessible sites, and a meaningful share of PVC-induced cardiomyopathy reverses with antiarrhythmic suppression alone once the burden comes down — we don't need a procedure to get the reversal, we need the ectopy controlled. A beta-blocker trial costs her little and tells us something real before we expose her to a catheter.
I'm not against ablation as a next step if medical therapy underperforms — I just don't think "it could be curative" should skip past "a lower-risk option might get us the same result."
If a drug trial is the first step, the sequence matters. Start with a beta-blocker — the lowest-risk option and a reasonable first attempt at suppressing burden. If that's not enough, the escalation question is harder than it looks. CAST's mortality signal against Class IC agents came from post-MI patients with ischemic scar, and she has none — but I don't want us to read that as clearance. An ejection fraction of 40% is itself a depressed ventricle, and Class IC agents carry a boxed warning that turns on ventricular dysfunction, not on its cause. Using flecainide here means arguing that a cardiomyopathy expected to reverse shouldn't count the way scar does, and that argument is genuinely made in this specific diagnosis, but it is off-label, center-dependent, and demands close monitoring — a repeat echocardiogram and ECG within weeks, not a prescription and a follow-up in three months. If we're not comfortable with that, amiodarone or sotalol are the alternatives that don't depend on the argument holding. Given her mapped, accessible focus, my own view is that ablation is the cleaner escalation and shouldn't be treated as the fallback after drugs fail.
Beta-blocker trial started first, with repeat Holter and echocardiogram in several weeks. If burden and ejection fraction don't improve, catheter ablation is the preferred escalation given her mapped and accessible focus; flecainide named as the alternative but explicitly flagged as off-label at her ejection fraction, contingent on close early re-imaging, with amiodarone or sotalol as the fallback if that caveat isn't acceptable. Ablation was kept active as a strong option throughout rather than held back as a last resort only after medical therapy fails outright.